DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
46	悪性関節リウマチ	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00782600 (ClinicalTrials.gov)	July 2008	27/10/2008	Study of Controlled Release Formulations of CE-224,535 Against the Immediate Release Formulation in Normal Volunteers	A Phase 1, Randomized, 4-Period, 4-Sequence Cross-Over Study Of The Pharmacokinetics Of 3 Durations Of Release Of A Controlled Release Formulation And A Single Dose Of An Immediate Release Oral Suspension Of CE-224,535 In Normal Healthy Volunteers	Rheumatoid Arthritis	Drug: suspension IR;Drug: CR 1;Drug: CR 2;Drug: CR 3	Pfizer	NULL	Completed	18 Years	55 Years	Both	16	Phase 1	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT00782600
(ClinicalTrials.gov)

July 2008

27/10/2008

Study of Controlled Release Formulations of CE-224,535 Against the Immediate Release Formulation in Normal Volunteers

A Phase 1, Randomized, 4-Period, 4-Sequence Cross-Over Study Of The Pharmacokinetics Of 3 Durations Of Release Of A Controlled Release Formulation And A Single Dose Of An Immediate Release Oral Suspension Of CE-224,535 In Normal Healthy Volunteers

Rheumatoid Arthritis

Drug: suspension IR;Drug: CR 1;Drug: CR 2;Drug: CR 3

Pfizer

NULL

Completed

18 Years

55 Years

Both

Phase 1

United States